Jan 11 (Reuters) - Immunovaccine Inc IMV.TO :
* Announces U.S. FDA, health Canada clearance to initiate phase 1b clinical
trial for dpx-survivac in combination with incyte's ido1 inhibitor
epacadostat in recurrent ovarian cancer
* Immunovaccine anticipates starting trial, which incyte will co-fund under
terms of agreement between two companies, by Q2 2016
* Source text for Eikon ID:nCCN9BMPWY
* Further company coverage IMV.TO